Allan Jonathan 4

What Happened

• Allan Jonathan, General Counsel & Corporate Secretary of Stoke Therapeutics (STOK), reported exercising/converting derivative awards (transaction code M) for a total of 25,475 shares on March 15, 2026 (7,475 + 6,000 + 12,000). The filing records both the acquisition and the immediate disposition of those same shares. The Form 4 reports $0 as the price for these transactions.

Key Details

• Transaction date: March 15, 2026; Form 4 filed March 17, 2026 (reporting period 2026-03-15).
• Reported quantities: 7,475; 6,000; and 12,000 shares — total 25,475 shares acquired and 25,475 shares disposed.
• Reported price/proceeds: $0.00 for each line in the filing (as reported on the Form 4).
• Shares owned after transaction: not stated in the provided excerpt of the filing.
• Notable footnotes:
  • F1: 425 shares were acquired under the company’s Employee Stock Purchase Plan (ESPP) in transactions exempt under Rules 16b-3(c)/(d).
  • F2–F5: Some awards are restricted stock units (RSUs) that vest over multi-year schedules (vesting schedules beginning March 15, 2024/2025/2026, with 1/4 vesting annually).
• Timeliness: filing date is two days after the transaction date (March 17 filing for March 15 transaction), consistent with standard Form 4 timing.

Context

• Transaction code M indicates exercise or conversion of a derivative (e.g., option exercise or RSU settlement). The matching acquisition and disposition entries suggest the shares were converted/settled and then immediately disposed of (often a cashless exercise or immediate sale), though the Form 4 here reports $0 and does not show sale proceeds.
• This type of reporting is typically routine (settlement of awards and immediate disposition) and does not, by itself, indicate a change in insider sentiment.